Goldman Sachs
CLDX icon

Goldman Sachs’s Celldex Therapeutics CLDX Stock Holding History

Goldman Sachs’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-25,200
Closed -$637K – 6105
2024
Q4 		$637K Hold
25,200
– – ﹤0.01% 5107
2024
Q3 		$857K Hold
25,200
– – ﹤0.01% 4743
2024
Q2 		$933K Hold
25,200
– – ﹤0.01% 4453
2024
Q1 		$1.06M Hold
25,200
– – ﹤0.01% 4317
2023
Q4 		$999K Buy
+25,200
New +$741K ﹤0.01% 4386
2015
Q3 		– Sell
-10,000
Closed -$3.78M – 7290
2015
Q2 		$3.78M Buy
+10,000
New +$3.97M ﹤0.01% 3199

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Goldman Sachs's CLDX Position: Q1 2026 in Review

Goldman Sachs reduced its Celldex Therapeutics (CLDX) stake by 7.5% in Q1 2026, selling an estimated $2.17M and leaving 988,416 shares worth $31.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2012.

Goldman Sachs first reported a position in CLDX in Q2 2013 and has held it in 46 quarters since. The position peaked at $62.4M in Q3 2024. 228 funds tracked by Wall St. Rank hold CLDX as of Q1 2026.

  • Goldman Sachs held 988,416 shares of Celldex Therapeutics worth $31.4M as of Q1 2026.
  • Goldman Sachs sold 79,715 Celldex Therapeutics shares in Q1 2026, an estimated $2.17M.
  • Celldex Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #2012 holding.
  • Goldman Sachs first reported a position in Celldex Therapeutics in Q2 2013 and has held it in 46 quarters since.
  • Goldman Sachs's Celldex Therapeutics position peaked at $62.4M in Q3 2024.
  • 228 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.